Structural and Functional View of Polypharmacology
暂无分享,去创建一个
John P. Overington | Jonathan G. Lees | Christine Orengo | Natalie L Dawson | John P Overington | Juan A G Ranea | C. Orengo | J. Lees | J. A. Ranea | N. Dawson | T. Adeyelu | Felix A. Kruger | A. Moya-García | Aurelio Moya-García | Tolulope Adeyelu | Felix A Kruger | Jon G Lees | Tolulope Adeyelu
[1] Damian Szklarczyk,et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..
[2] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[3] W R Taylor,et al. Protein structure alignment. , 1989, Journal of molecular biology.
[4] H. Burris,et al. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. , 2004, The oncologist.
[5] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[6] Jürgen Bajorath,et al. Many structurally related drugs bind different targets whereas distinct drugs display significant target overlap , 2012 .
[7] W R Taylor,et al. SSAP: sequential structure alignment program for protein structure comparison. , 1996, Methods in enzymology.
[8] A. Barabasi,et al. Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.
[9] James H. Doroshow,et al. Safety and feasibility of targeted agent combinations in solid tumours , 2013, Nature Reviews Clinical Oncology.
[10] Benjamin A. Shoemaker,et al. IBIS (Inferred Biomolecular Interaction Server) reports, predicts and integrates multiple types of conserved interactions for proteins , 2011, Nucleic Acids Res..
[11] C. Chothia,et al. Evolution of the Protein Repertoire , 2003, Science.
[12] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[13] John P. Overington,et al. Mapping small molecule binding data to structural domains , 2012, BMC Bioinformatics.
[14] E V Koonin,et al. Estimating the number of protein folds and families from complete genome data. , 2000, Journal of molecular biology.
[15] Christine A. Orengo,et al. Protein function prediction using domain families , 2013, BMC Bioinformatics.
[16] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[17] Yoshihiro Yamanishi,et al. Extracting Sets of Chemical Substructures and Protein Domains Governing Drug-Target Interactions , 2011, J. Chem. Inf. Model..
[18] Sarah A. Teichmann,et al. An insight into domain combinations , 2001, ISMB.
[19] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[20] Jordi Mestres,et al. Polypharmacology in Precision Oncology: Current Applications and Future Prospects , 2016, Current pharmaceutical design.
[21] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[22] U. Bhalla,et al. Functional modules in biological signalling networks. , 2001, Novartis Foundation symposium.
[23] Christine A. Orengo,et al. Finding the “Dark Matter” in Human and Yeast Protein Network Prediction and Modelling , 2010, PLoS Comput. Biol..
[24] John P. Overington,et al. PPDMs—a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains , 2014, Bioinform..
[25] J. A. Ranea,et al. Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies , 2016, Oncotarget.
[26] T. Geppert,et al. Biological Networks and Drug Discovery—Where Do We Stand? , 2014, Drug development research.
[27] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[28] Erli Pang,et al. Promiscuous domains: facilitating stability of the yeast protein-protein interaction network. , 2012, Molecular bioSystems.
[29] M. Rask-Andersen,et al. The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. , 2014, Annual review of pharmacology and toxicology.
[30] J. Lees,et al. Defining functional interactions during biogenesis of epithelial junctions , 2016, Nature Communications.
[31] Peter S. Kutchukian,et al. Rethinking molecular similarity: comparing compounds on the basis of biological activity. , 2012, ACS chemical biology.
[32] Juancarlos Chan,et al. Gene Ontology Consortium: going forward , 2014, Nucleic Acids Res..
[33] E. Raymond,et al. Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer , 2009, Drug safety.
[34] A. Barabasi,et al. Lethality and centrality in protein networks , 2001, Nature.
[35] Tapio Salakoski,et al. An expanded evaluation of protein function prediction methods shows an improvement in accuracy , 2016, Genome Biology.
[36] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[37] M. Rask-Andersen,et al. Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.
[38] R. Iyengar,et al. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.
[39] E. Koonin,et al. The structure of the protein universe and genome evolution , 2002, Nature.
[40] Peer Bork,et al. The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..
[41] Vincent Le Guilloux,et al. Fpocket: An open source platform for ligand pocket detection , 2009, BMC Bioinformatics.
[42] Prudence Mutowo-Meullenet,et al. The GOA database: Gene Ontology annotation updates for 2015 , 2014, Nucleic Acids Res..
[43] E. Birney,et al. Pfam: the protein families database , 2013, Nucleic Acids Res..
[44] Antonio Lavecchia,et al. In silico methods to address polypharmacology: current status, applications and future perspectives. , 2016, Drug discovery today.
[45] Patrick Aloy,et al. IntSide: a web server for the chemical and biological examination of drug side effects , 2014, Bioinform..
[46] Haiyuan Yu,et al. Three-dimensional reconstruction of protein networks provides insight into human genetic disease , 2012, Nature Biotechnology.
[47] A G Murzin,et al. SCOP: a structural classification of proteins database for the investigation of sequences and structures. , 1995, Journal of molecular biology.
[48] Hadley Wickham,et al. ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .
[49] Adam Godzik,et al. Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences , 2006, Bioinform..
[50] Haiyuan Yu,et al. Target Essentiality and Centrality Characterize Drug Side Effects , 2013, PLoS Comput. Biol..
[51] Peter Dalgaard,et al. R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .
[52] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[53] Jürgen Bajorath,et al. Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs , 2010, J. Chem. Inf. Model..
[54] Alfonso Valencia,et al. Integration of biological data by kernels on graph nodes allows prediction of new genes involved in mitotic chromosome condensation , 2014, Molecular biology of the cell.
[55] E. Berg. Systems biology in drug discovery and development. , 2014, Drug discovery today.
[56] Benoit H. Dessailly,et al. Functional site plasticity in domain superfamilies☆ , 2013, Biochimica et biophysica acta.
[57] Miguel Ángel Medina,et al. Systems biology for molecular life sciences and its impact in biomedicine , 2012, Cellular and Molecular Life Sciences.
[58] Patrick Aloy,et al. Analysis of chemical and biological features yields mechanistic insights into drug side effects. , 2013, Chemistry & biology.
[59] Sarah A. Teichmann,et al. Protein domain organisation: adding order , 2009, BMC Bioinformatics.
[60] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[61] Aurelio A. Moya-García,et al. Insights into polypharmacology from drug-domain associations , 2013, Bioinform..
[62] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[63] Adam Godzik,et al. Analysis of Individual Protein Regions Provides Novel Insights on Cancer Pharmacogenomics , 2015, PLoS Comput. Biol..
[64] I. Morilla,et al. Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity , 2014 .
[65] David A. Lee,et al. Functional classification of CATH superfamilies: a domain-based approach for protein function annotation , 2015, Bioinform..
[66] X. Barril,et al. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. , 2010, Journal of medicinal chemistry.
[67] R. Sharan,et al. Network-based prediction of protein function , 2007, Molecular systems biology.
[68] Ruth Nussinov,et al. Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.
[69] G. Maggiora,et al. Molecular similarity in medicinal chemistry. , 2014, Journal of medicinal chemistry.
[70] Dietrich Rebholz-Schuhmann,et al. The functional therapeutic chemical classification system , 2013, Bioinform..
[71] Daniel W. A. Buchan,et al. A large-scale evaluation of computational protein function prediction , 2013, Nature Methods.
[72] E. Freire,et al. Finding a better path to drug selectivity. , 2011, Drug discovery today.
[73] Olaf Wolkenhauer,et al. Evolution of Centrality Measurements for the Detection of Essential Proteins in Biological Networks , 2016, Front. Physiol..
[74] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[75] David C. Jones,et al. CATH--a hierarchic classification of protein domain structures. , 1997, Structure.
[76] Andrew B. Clegg,et al. CODA: Accurate Detection of Functional Associations between Proteins in Eukaryotic Genomes Using Domain Fusion , 2010, PloS one.
[77] E. Blomme,et al. Potential functional and pathological side effects related to off-target pharmacological activity. , 2017, Journal of pharmacological and toxicological methods.
[78] Davide Heller,et al. STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..
[79] C. Sander,et al. Automated Network Analysis Identifies Core Pathways in Glioblastoma , 2010, PloS one.
[80] Aric Hagberg,et al. Exploring Network Structure, Dynamics, and Function using NetworkX , 2008, Proceedings of the Python in Science Conference.
[81] Philip M. Kim,et al. Evolution of biological interaction networks: from models to real data , 2011, Genome Biology.
[82] Avi Ma'ayan,et al. Lean Big Data integration in systems biology and systems pharmacology. , 2014, Trends in pharmacological sciences.
[83] Christine A. Orengo,et al. Gene3D: merging structure and function for a Thousand genomes , 2009, Nucleic Acids Res..
[84] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[85] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[86] David A. Lee,et al. GeMMA: functional subfamily classification within superfamilies of predicted protein structural domains , 2009, Nucleic acids research.
[87] Jame Abraham,et al. Lapatinib in the treatment of breast cancer , 2007, Expert review of anticancer therapy.
[88] T. Ramsay,et al. Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. , 2016, Journal of the National Cancer Institute.
[89] Jürgen Bajorath,et al. Rationalizing Structure and Target Relationships between Current Drugs , 2012, The AAPS Journal.
[90] J. Hopfield,et al. From molecular to modular cell biology , 1999, Nature.
[91] C. Myers,et al. Using networks to measure similarity between genes: association index selection , 2013, Nature Methods.
[92] Tudor I. Oprea,et al. A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.
[93] Philip S. Yu,et al. A new method to measure the semantic similarity of GO terms , 2007, Bioinform..
[94] Ian Sillitoe,et al. Gene3D: a domain-based resource for comparative genomics, functional annotation and protein network analysis , 2011, Nucleic Acids Res..
[95] David A. Lee,et al. CATH: comprehensive structural and functional annotations for genome sequences , 2014, Nucleic Acids Res..
[96] S. Lampel,et al. The druggable genome: an update. , 2005, Drug discovery today.
[97] E. Smit,et al. Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[98] Yibo Wu,et al. GOSemSim: an R package for measuring semantic similarity among GO terms and gene products , 2010, Bioinform..
[99] Mark Gerstein,et al. The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..
[100] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[101] Piet Van Mieghem,et al. Topology of molecular interaction networks , 2013, BMC Systems Biology.
[102] Samik Ghosh,et al. Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology , 2015, npj Systems Biology and Applications.
[103] Shuxing Zhang,et al. Computational polypharmacology: a new paradigm for drug discovery , 2017, Expert opinion on drug discovery.